© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.
James Allison and Tasuku Honjo recognized for immune checkpoint discoveries.
The experimental antibody BAY1905254 targets the newly discovered checkpoint ILDR2.
Taking the brakes off the immune system can lead to excessive responses that harm healthy organs and tissue.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
